PDF herunterladen
TumorDiagnostik & Therapie 2017; 38(02): 95-99
DOI: 10.1055/s-0043-100427
Schwerpunkt Endometrium- und Zervixkarzinome
© Georg Thieme Verlag KG Stuttgart · New York

HPV-Infektionen: Diagnostik und Impfung

Kay Neumann
1   Universitätsklinikum Schleswig-Holstein, Campus Lübeck
,
Markus Cavalar
2   Euroimmun Medizinische Labordiagnostika AG, Lübeck
,
Achim Rody
1   Universitätsklinikum Schleswig-Holstein, Campus Lübeck
,
Daniel Alexander Beyer
3   Klinik für Frauenheilkunde und Geburtshilfe, Westpfalz-Klinikum GmbH, Kaiserslautern
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
06. März 2017 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Humane Papillomaviren (HPV) sind doppelsträngige DNA-Viren, von denen > 200 verschiedene Subtypen bekannt sind. Die HPV-Subtypen lassen sich je nach malignem Potenzial einer Infektion entweder in Niedrigrisikosubtypen (6, 11, 40, 42, 43, 44, etc.) oder Hochrisikosubtypen (6, 18, 31, 33, 35, 39 etc.) einteilen. Die häufigsten Hochrisikosubtypen sind HPV 16 und 18 (verantwortlich für 70 % der Zervixkarzinome) [1]. Die Infektion mit HPV Niedrigrisikosubtypen kann zu gutartigen Feigwarzen oder Larynxpapillomatose führen, während eine Infektion mit Hochrisikosubtypen zu invasiven Karzinomen insbesondere dem Zervixkarzinom aber auch Karzinomen des Mund-Rachenraums, Vagina-, Vulva-, Penis- und Analkarzinomen führen kann [2].

Bei Zervixkarzinomen lässt sich in 99,7 % DNA von Hochrisiko-HPV nachweisen. Bereits 1976 postulierte Harald zur Hausen, dass die Infektion mit HPV einen essenziellen Faktor bei der Pathogenese des Zervixkarzinoms darstellt, wofür er 2008 mit dem Medizin-Nobelpreis ausgezeichnet wurde.

International variiert die Prävalenz von HPV-Infektionen in Abhängigkeit von Kulturkreis, sozialer Schicht und Alter und liegt zwischen 3 % –50 % [3] [4]. In Westeuropa wird die Prävalenz von humanen Papillomaviren bei Frauen auf ca. 9 % geschätzt, wobei es einen Altersgipfel bei 20 – 24 Jahren mit einer Prävalenz von 29 – 45 % gibt [5] [6] [7].

Infektionen mit HPV finden häufig schon bei den ersten Sexualkontakten statt [8]. Kondome stellen keinen absoluten Schutz vor der Übertragung dar, können aber vermutlich die Wahrscheinlichkeit einer Übertragung verringern [9]. Bislang wurde eine Reihe von Risikofaktoren für eine HPV-Infektion identifiziert ([Tab. 1]) [10] [11] [12] [13].

Tab. 1

Risikofaktoren für eine HPV-Infektion.

Promiskuität

niedriger sozioökonomischer Status

Immunsuppression

früher Geschlechtsverkehr

Rauchen

Multiparität

Einnahme oraler Kontrazeptiva > 5 Jahre

Ko-Infektion mit sexuell übertragbaren Erregern
 

  • Literatur

  • 1 Bzhalava D. Guan P. Franceschi S. et al. A systematic review of the prevalence of mucosaland cutaneous human papillomavirus types. Virology 2013; 445: 224-231
    CrossrefPubMedGoogle Scholar
  • 2 Cavalar M. Beyer D. Humane Papillomaviren Karzinogenese, Nachweismethoden, Impfstrategien. Gynäkologe 2016; 49: 311-318
    CrossrefPubMedGoogle Scholar
  • 3 Schneider A. Hoyer H. Lotz B. et al. Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. Int J Cancer 2000; 89: 529-534
    CrossrefPubMedGoogle Scholar
  • 4 Van Den Brule AJC. Walboomers JMM. Maine MD. et al. Difference in prevalence of human papillomavirus genotypes in cytomorphologically normal cervical smears is associated with a history of cervical intraepithelial neoplasia. Int J Cancer 1991; 48: 404-408
    CrossrefPubMedGoogle Scholar
  • 5 Bruni L. Diaz M. Castellsague X. et al. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010; 202: 1789-1799
    CrossrefPubMedGoogle Scholar
  • 6 de Sanjose S. Diaz M. Castellsague X. et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007; 7: 453-459
    CrossrefPubMedGoogle Scholar
  • 7 De Vuyst H. Clifford G. Li N. et al. HPV infection in Europe. Europ J Cancer 2009; 45: 2632-2639
    CrossrefPubMedGoogle Scholar
  • 8 Braly P. Preventing cervical cancer. Nat Med 1996; 2: 749-751
    CrossrefPubMedGoogle Scholar
  • 9 Manhart LE. Koutsky LA. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex Transm Dis 2002; 29: 725-735
    CrossrefPubMedGoogle Scholar
  • 10 Gadducci A. Barsotti C. Cosio S. et al. Smoking habit, immune suppression, oral contraceptive use, and hormone replacement therapy use and cervical carcinogenesis: a review of the literature. Gynecol Endocrinol 2011; 27: 597-604
    CrossrefPubMedGoogle Scholar
  • 11 Plummer M. Herrero R. Franceschi S. et al. Smoking and cervical cancer: pooled analysis of the IARC multi-centric case-control study. Cancer Causes Contr 2003; 14: 805-814
    CrossrefPubMedGoogle Scholar
  • 12 Castellsague X. Munoz N. Chapter 3: Cofactors in human papillomavirus carcinogenesis – role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr 2003; 31: 20-28
    PubMedGoogle Scholar
  • 13 Appleby P. Beral V. Berrington de González A. et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16573 women with cervical cancer and 35509 women without cervical cancer from 24 epidemiological studies. Lancet 2007; 370: 1609-1621
    CrossrefPubMedGoogle Scholar
  • 14 Doorbar J. Quint W. Banks L. et al. The biology and life-cycle of human papillomaviruses. Vaccine 2012; 30: 55-70
    CrossrefPubMedGoogle Scholar
  • 15 Schiffman M. Castle PE. Jeronimo J. et al. Human papillomavirus and cervical cancer. Lancet 2007; 370: 890-907
    CrossrefPubMedGoogle Scholar
  • 16 Cullen AP. Reid R. Campion M. et al. Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasm. J Virol 1991; 65: 606-612
    PubMedGoogle Scholar
  • 17 Hopman AH. Smedts F. Dignef W. et al. Transition of high-grade cervical intraepithelial neoplasia to micro-invasive carcinoma is characterized by integration of HPV 16/18 and numerical chromosome abnormalities. J Pathol 2004; 202: 23-33
    CrossrefPubMedGoogle Scholar
  • 18 Matsukura T. Sugase M. Pitfalls in the epidemiologic classification of human papillomavirus types associated with cervical cancer using polymerase chain reaction: driver and passenger. Int J Gynecol Cancer 2008; 18: 1042-1050 . Erratum in: Int J Gynecol Cancer 2008; 18: 1388
    CrossrefPubMedGoogle Scholar
  • 19 Ganguly N. Parihar SP. Human papillomavirus E6 and E7 oncoproteins as risk factors for tumorigenesis. J Biosci 2009; 34: 113-123
    CrossrefPubMedGoogle Scholar
  • 20 Dickson EL. Vogel RI. Geller MA. et al. Cervical cytology and multiple type HPV infection: a study of 8182 women ages 31–65. Gynecol Oncol 2014; 133: 405-408
    CrossrefPubMedGoogle Scholar
  • 21 Östor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993; 12: 186-192
    PubMedGoogle Scholar
  • 22 Cuzick J. Clavel C. Petry KU. et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006; 119: 1095-1101
    CrossrefPubMedGoogle Scholar
  • 23 Coste J. Cochand-Priollet B. Le GC. et al. Cross sectional study of conventional cervical smear, monolayer cytology, and human papillomavirus DNA testing for cervical cancer screening. Brit Med J 2003; 326: 733
    CrossrefPubMedGoogle Scholar
  • 24 Mayrand MH. Duarte-Franco E. Rodrigues I. et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007; 357: 1579-1588
    CrossrefPubMedGoogle Scholar
  • 25 Bauer HM. Ting Y. Greer CE. et al. Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA 1991; 265: 472-477
    CrossrefPubMedGoogle Scholar
  • 26 Castle PE. Stoler MH. Wright TC. et al. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol 2011; 12: 880-890
    CrossrefPubMedGoogle Scholar
  • 27 Poljak M. Kocjan BJ. Ostrbenk A. et al. Commercially available molecular tests for human papillomaviruses (HPV): 2015 update. J Clin Virol 2016; 76: S3-S13
    CrossrefPubMedGoogle Scholar
  • 28 Meijer CJ. Berkhof J. Castle PE. et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 2009; 124: 516-520
    CrossrefPubMedGoogle Scholar
  • 29 Elfgren K. Elfstrom KM. Naucler P. et al. Management of women with human papillomavirus persistence: long-term follow-up of a randomized clinical trial. Am J Obstet Gynecol 2016; DOI: 10.1016/j.ajog.2016.10.042.
    CrossrefPubMedGoogle Scholar
  • 30 Schmitt M. Depuydt C. Benoy I. et al. Multiple human papillomavirus infections with high viral loads are associated with cervical lesions but do not differentiate grades of cervical abnormalities. J Clin Microbiol 2013; 51: 1458-1464
    CrossrefPubMedGoogle Scholar
  • 31 Delere Y. Remschmidt C. Leuschner J. et al. Human Papillomavirus prevalence and probable first effects of vaccination in 20 to 25 year-old women in Germany: a population-based cross-sectional study via home-based self-sampling. BMC Infect Dis 2014; 14: 87
    CrossrefPubMedGoogle Scholar
  • 32 Ganguly N. Parihar SP. Human papillomavirus E6 and E7 oncoproteins as risk factors for tumorigenesis. J Biosci 2009; 34: 113-123
    CrossrefPubMedGoogle Scholar
  • 33 Jeon S. Lambert PF. Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis. Proc Natl Acad Sci USA 1995; 92: 1654-1658
    CrossrefPubMedGoogle Scholar
  • 34 Jeon S. len-Hoffmann BL. Lambert PF. Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells. J Virol 1995; 69: 2989-2997
    PubMedGoogle Scholar
  • 35 Karlsen F. Kalantari M. Jenkins A. et al. Use of multiple PCR primer sets for optimal detection of human papillomavirus. J Clin Microbiol 1996; 34: 2095-2100
    PubMedGoogle Scholar
  • 36 Romanczuk H. Howley PM. Disruption of either the E1 or the E2 regulatory gene of human papillomavirus type 16 increases viral immortalization capacity. Proc Natl Acad Sci USA 1992; 89: 3159-3163
    CrossrefPubMedGoogle Scholar
  • 37 Morris BJ. Cervical human papillomavirus screening by PCR: advantages of targeting the E6 / E7 region. Clin Chem Lab Med 2005; 43: 1171-1177
    PubMedGoogle Scholar
  • 38 Tjalma WA. Depuydt CE. Cervical cancer screening: which HPV test should be used – L1 or E6 / E7?. Eur J Obstet Gynecol Reprod Biol 2013; 170: 45-46
    CrossrefPubMedGoogle Scholar
  • 39 Speich N. Schmitt C. Bollmann R. et al. Human papillomavirus (HPV) study of 2916 cytological samples by PCR and DNA sequencing: genotype spectrum of patients from the west German area. J Med Microbiol 2004; 53: 125-128
    CrossrefPubMedGoogle Scholar
  • 40 Castle PE. Dockter J. Giachetti C. et al. A cross-sectional study of a prototype carcinogenic human papillomavirus E6 / E7 messenger RNA assay for detection of cervical precancer and cancer. Clin Cancer Res 2007; 13: 2599-2605
    CrossrefPubMedGoogle Scholar
  • 41 Villa LL. Costa RL. Petta CA. et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 271-278
    CrossrefPubMedGoogle Scholar
  • 42 Harper DM. Franco EL. Wheeler C. et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364: 1757-1765
    CrossrefPubMedGoogle Scholar
  • 43 Giannini SL. Hanon E. Moris P. et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006; 24: 5937-5949
    CrossrefPubMedGoogle Scholar
  • 44 Fachinformation GARDASIL® 9. sanofi-pasteur MSD 10.07.2016. Abgerufen von www.impfservice.de/fileadmin/user_upload/pdfs/Fachinformationen/FI_Gardasil9_05-2016_RLFS.pdf
    PubMedGoogle Scholar
  • 45 Robert Koch-Institut. Impfung gegen humane Papillomaviren (HPV) für Mädchen von 12 bis 17 Jahren – Empfehlung und Begründung. Epidemiologisches Bulletin 2007; 12: 99
    PubMedGoogle Scholar
  • 46 Joura EA. Garland SM. Paavonen J. et al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. Brit Med J 2012; 344: e1401
    CrossrefPubMedGoogle Scholar
  • 47 Poethko-Müller C. Buttmann-Schweiger N. KiGGS Study Group HPV vaccination coverage in German girls: results of the KiGGS study: first follow-up (KiGGS Wave 1). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2014; 57: 869-877
    CrossrefPubMedGoogle Scholar
  • 48 Ali H. Guy RJ. Wand H. et al. Decline in in-patient treatments of genital warts among young Australians following the national HPV vaccination program. BMC Infect Dis 2013; 13: 140
    CrossrefPubMedGoogle Scholar
  • 49 Donovan B. Franklin N. Guy R. et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2011; 11: 39-44
    CrossrefPubMedGoogle Scholar
  • 50 Fairley CK. Hocking JS. Gurrin LC. et al. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. Sex Transm Infect 2009; 85: 499-502
    CrossrefPubMedGoogle Scholar
  • 51 Read TR. Hocking JS. Chen MY. et al. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2011; 87: 544-547
    CrossrefPubMedGoogle Scholar
  • 52 Gross G. et al. Impfprävention HPV-assoziierter Neoplasien. 2013 Abgerufen von: www.awmf.org/leitlinien/detail/ll/082-002.html
    PubMedGoogle Scholar
  • 53 Brotherton JM. Fridman M. May CL. et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011; 377: 2085-2092
    CrossrefPubMedGoogle Scholar